On Sunday, July 7, 2024, we exhibited at the Institute for Predictable Osseointegration in Implantology (IPOI), a non-profit organization (NPO) event held in Fukuoka City.
Mediplus Pharma, Inc. presented the safety and efficacy of its proprietary ingredient, ozonized glycerin (Novel Glycerin Compound), in formulations for atopic dermatitis at the 123rd Annual Meeting of the Japanese Dermatological Association. The conference was held from June 6 to June 9, 2024, at the Kyoto International Conference Center. For more details on the press release, please visit here.https://prtimes.jp/main/html/rd/p/000000015.000079724.html
Mediplus Pharma, Inc. (CEO: Kenji Ito, HQ: Shibuya, Tokyo) presented on the multifunctionality and application of its proprietary ingredient, ozonized glycerin (Novel Glycerin Compound), as biomaterials at the 12th World Biomaterials Congress (WBC), held over six days from May 26 to 31, 2024, in Daegu, South Korea. For more details on the press release, please visit here.https://prtimes.jp/main/html/rd/p/000000013.000079724.html
We are pleased to announce our participation in the 16th Academic Conference of the Non-Profit Organization (NPO) Institute for Predictable Osseointegration in Implantology, which will be held on Sunday, July 7, 2024, in Fukuoka City.We aim to introduce our unique ingredient , ozonized glycerin, which is expected to have beneficial effects in dental medicine, particularly in the surgical field. This […]
A presentation on the safety and efficacy evaluation of atopic dermatitis was held at the American Academy of Dermatology (AAD) in March, and it has been featured in the “Health Industry Distribution Newspaper” issue 1111 (published on 4/25). We plan to continue utilizing Novel Glycerin Compounds (ozonized glycerin) extensively in the business ventures undertaken by our group companies in the […]
We are pleased to announce the launch of our new patent information page.PATENTThis page provides disclosures of the patent registration information that we possess. Interested parties are invited to explore this resource to better understand it further.
It is an enzyme that inactivates penicillin.
It is a compound produced by microorganisms that has the effect of inhibiting the growth of other microorganisms and cells.
Methicillin is an antibiotic of the penicillin class. It is rarely used because it is unstable and difficult to handle in medical facilities.
Staphylococcus epidermidis is a commensal bacterium found on human skin surfaces and in nasal cavities. It lacks the variety of toxins found in Staphylococcus aureus, but it can still cause infections particularly in individuals with implants and catheters.
